PUF Ventures to Build 1 Million-Square-Foot
Seite 4 von 45
neuester Beitrag: 06.06.20 17:01
|eröffnet am:||27.09.17 15:32 von:||GoldenStock||Anzahl Beiträge:||1122|
|neuester Beitrag:||06.06.20 17:01 von:||hollysuh||Leser gesamt:||195875|
|bewertet mit 5 Sternen
GoldenStock : Wohl nur eine Frage der Zeit, bis auch PUF wieder
GoldenStock : Hier die News - teilweise auch PUF betreffend :
SOURCE USA News Group
LOS ANGELES, November 10, 2017 /PRNewswire/ --
Despite being behind Canada and the U.S. on the legal curve of medical and recreational marijuana adoption, Australia is taking big steps towards competing with the leading markets. Several partnerships, including one to build a one million square foot cannabis production facility in the country, are helping Australia to play catch up.
Cannabis companies experiencing positive momentum from these advances include MYM Nutraceuticals Inc. (CSE: MYM) (OTC: MYMMF), Organigram Holdings Inc. (TSX-V: OGI) (OTC: OGRMF), CanniMed Therapeutics Inc. (TSX: CMED) (OTC: CMMDF), and Supreme Pharmaceuticals Inc. (TSX-V: FIRE) (OTC: SPRWF).
It appears that Australia may be the next major nation looking to liberalize how it handles the application of cannabis with serious efforts to bolster its growing industry.
In a recent news release, Canadian firm MYM Nutraceuticals Inc. (CSE: MYM) (OTCQB: MYMMF) announced that it entered a strategic partnership with PUF Ventures Inc. (an Australian government-owned venture) for the construction of a one million square foot greenhouse facility in northern New South Wales, Australia known as the Northern Rivers Project.
This would make the facility one of the largest dedicated cannabis growing operations in the world and certainly the largest in Australia.
It seems that MYM Nutraceuticals Inc. is an obvious choice for this unique partnership. MYM is a young company, but it is already developing of some of the world's largest cannabis greenhouses, as well as diversified interests in cannabis derivatives, formulations and distribution.
Analysts are reacting positively to the news with the sentiment that moving down this road can directly benefit other companies already dealing in legal cannabis. These include Licensed Producers, medicinal marijuana companies developing therapeutics and more diversified cannabis companies including Organigram Holdings Inc. (TSX-V: OGI) (OTCQB: OGRMF), CanniMed Therapeutics Inc. (TSX: CMED) (OTCMKTS: CMMDF), and Supreme Pharmaceuticals Inc. (TSX-V: FIRE) (OTC: SPRWF).
DOWN UNDER CANNABIS
Australia has continuously introduced progressive medical cannabis laws in the past few years, and is very much positioned about where Canada was about four years ago.
Assuming recreational cannabis becomes legal there and with a population of more than 24 million people, it is estimated that Australia's cannabis market could grow to roughly CDN $9 billion over the next seven years. This makes Australia a very attractive market, especially for existing producers in Canada and the U.S.
Being one of the first large-scale production facilities in the Australian market, MYM and PUF stand to capture a significant portion of that potential revenue and take a first-mover position.
NOT THEIR FIRST RODEO
The Northern Rivers Project includes a land purchase option agreement with the local government for a 27-hectare parcel of land near the town of Casino in northern New South Wales. This is a landmark agreement whereby the Richmond Valley Council will provide the land for five years at no cost, with an option for Northern Rivers Project to purchase the parcel on favorable terms after year five.
The Richmond Valley Council has been extremely supportive of Northern Rivers Project's growth strategy and vision. For the council, it's a move to improve local economic and employment opportunities.
The construction of the growing facility will be completed in stages at an estimated total cost of CDN $50 million. The first phase of the project covers about 300,000 square feet, which upon completion, will be the largest medical cannabis greenhouse in Australia.
Based on current timelines, permitting and various Australian approvals, MYM and PUF say the first crop is expected to be planted in the fourth quarter of 2018.
If this arrangement sounds familiar, it is. MYM Nutraceuticals negotiated a similar agreement for its Weedon, Quebec growing facility in Canada.
Through its majority-owned subsidiary CannCanada, MYM signed an exclusive deal with the Quebec municipality of Weedon to build a 1.5 million square foot facility in 2016.
The town of Weedon itself is acquiring the 329 acres of land in order for MYM to establish its new megastructure. At completion, Weedon will be one of the largest greenhouse facilities dedicated to marijuana growth in the world, expected to produce over 150,000 kg of cannabis per year.
MYM is also developing a smaller growing facility in Laval, Quebec which it expects to have online in by the end of this year.
HELPING CREATE THE BOOM
Along with growing and cultivation at Weedon, Laval and Casino, MYM is creating its own unique integration path with brands, formulations and distribution capacity for its cannabis-based brands that include Joshua Tree, MyHemp Skin Therapy, and HempMed.
The HempMed line features custom-made cannabis products with tailored CBD chemistries to treat specific medical conditions and symptoms. They already offer more than 20 products including tinctures, concentrates and oils, edibles, vape products and pet care products.
MYM Nutraceuticals also boats first-in-class R&D in developing the highest quality cannabis-based nutraceuticals.
The company is moving at a breakneck pace toward establishing significant production capabilities backed by fully integrated R&D, products and distribution. The addition of the Australian interests opens the boundaries and makes MYM truly international.
It appears that their Australian partners see MYM Nutraceuticals as a logical fit for their growth plans and the country is fertile ground for this stage of development.
Australia's government is willing to embrace the legalization and integration of cannabis, at least for medicinal applications at present. The country is following other jurisdictions' models of steady-paced adoption.
The global cannabis market is experiencing a true growth boom and there are several mostly untapped regions. Australia, while it may take time to evolve, is a good place to lay the seedbed for what may be an integral part of the global cannabis market.
MYM and PUF are certainly at the jump off point for the next major stage of growth.
Organigram Holdings Inc. (TSX-V: OGI) (OTCQB: OGRMF)
Organigram Holdings Inc. is a TSX Venture Exchange listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of medical marijuana in Canada. Organigram is focused on producing the highest quality, condition specific medical marijuana for patients in Canada. Organigram's facility is located in Moncton, New Brunswick and the Company is regulated by the Marihuana for Medical Purposes Regulations.
CanniMed Therapeutics Inc (TSX: CMED) (OTCMKTS: CMMDF)
CanniMed Therapeutics Inc. is a Canadian-based, international plant biopharmaceutical company and a leader in the Canadian medical cannabis industry. CMED has an active plant biotechnology research and product development program focused on the production of plant-based materials for pharmaceutical, agricultural and environmental applications. Its subsidiary CanniMed Ltd., was the first producer to be licensed under the Marihuana for Medical Purposes Regulations (MMPR), the predecessor to the current Access to Cannabis for Medical Purposes Regulations (ACMPR). The company also owns strategic assets to service the potential medical cannabis market in the United States.
Supreme Pharmaceuticals Inc. (TSX-V: FIRE) (OTC: SPRWF),
Supreme Pharmaceuticals, through its wholly owned subsidiary, 7ACRES, is one of the first 40 federally licensed Canadian producers of medical cannabis pursuant to the ACMPR. The company operates inside a 342,000 sq. ft. Hybrid Greenhouse facility located in Kincardine, Ontario. It is the largest facility of its kind to grow with advanced HVAC and C02 enrichment using the full-spectrum sun. The company has commenced its first sales of dried cannabis to Aurora Cannabis, possibly the largest and most trusted retail brand in the Canadian industry.
For a more in-depth look into MYM you can view the in-depth report at USA News Group: usanewsgroup.com/2017/11/06/...ana_boom_is_here_to_stay-2-2-2/
USA News Group
Legal Disclaimer/Disclosure: This piece is an advertorial and has been paid for. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this Report should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. We make no guarantee, representation or warranty and accept no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of USA News Group only and are subject to change without notice. USA News Group assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this Report.
DISCLAIMER: USA News Group is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with USA News Group or any company mentioned herein. The commentary, views and opinions expressed in this release by USA News Group are solely those of USA News Group and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release.
FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Media Contact Information:
FN Media Group, LLC
Media Contact e-mail: firstname.lastname@example.org
U.S. Phone: +1(954)345-0611
©2017 PR Newswire. All Rights Reserved.
p0wly : Vergleich PUF Ventures mit Big Playern
anderswo : @ Mr. Cashh
wird da über die Verteilung von Aktien von Weed Point ehemals Vapetronix (für Stammaktionäre Stichtag 03.10.) gesprochen oder geht es da um einen Spin off? weißt du da mehr?
anderswo : Puf newslettet
Vancouver, British Columbia / November 27th, 2017 ? PUF Ventures Inc. (?PUF? or the ?Company?) (CSE: PUF) (Frankfurt: PU3) (OTCPK: PUFXF), is pleased to announce the results of its Annual General and Special Meeting held on November 24, 2017. All resolutions presented to the shareholders were overwhelmingly approved (see the SEDAR filing of the Company?s Information Circular dated October 20, 2017).
?The support we have received from our shareholders at the AGSM and through the conversion of warrants is tremendous, and a direct result of the progress made by PUF Ventures in 2017,? said Derek Ivany, President and CEO of PUF. ?The additional capital from warrants strengthens our balance sheet and I am very pleased with the progress being made by the Weed Points Loyalty team. I very much look forward to 2018 which I expect to be another exciting year for the company and our shareholders.?
Shareholders voted in favour of setting the number of directors at four and the following directors were re-elected: Derek Ivany, Chris Hornung, Jerry Habuda, and Joseph Perino. Shareholders also approved the plan of arrangement, which involves the distribution of common shares of Weed Points Loyalty Inc. dba TechOneSixty (?Weed Points?) to the shareholders of the Company.
The Company is also please to announce that in the past 60 days, it has received proceeds of $1,858,760 from the exercise of warrants. Proceeds raised are for general working capital purposes.
The Company also reports that security components have arrived at the London, ON grow facility and the installation of the necessary security enhancements and protocols is underway.
anderswo : übersetzung via Google
Vancouver, British Columbia / 27. November 2017 - PUF Ventures Inc. ("PUF" oder das "Unternehmen") (CSE: PUF) (Frankfurt: PU3) (OTCPK: PUFXF), freut sich, die Ergebnisse ihres jährlichen und Sondersitzung am 24. November 2017. Alle den Aktionären vorgelegten Beschlüsse wurden mit überwältigender Mehrheit angenommen (siehe die SEDAR-Einreichung des Informationsrundschreibens der Gesellschaft vom 20. Oktober 2017).
"Die Unterstützung, die wir von unseren Aktionären bei der AGSM und durch die Umwandlung von Optionsscheinen erhalten haben, ist enorm und ein direktes Ergebnis der Fortschritte von PUF Ventures im Jahr 2017", sagte Derek Ivany, Präsident und CEO von PUF. "Das zusätzliche Kapital aus Optionsscheinen stärkt unsere Bilanz und ich bin sehr zufrieden mit den Fortschritten des Weed Points Loyalty Teams. Ich freue mich sehr auf das Jahr 2018, von dem ich erwarte, dass es ein weiteres aufregendes Jahr für das Unternehmen und unsere Aktionäre sein wird. "
Die Aktionäre stimmten dafür, die Zahl der Direktoren auf vier festzusetzen, und die folgenden Direktoren wurden wiedergewählt: Derek Ivany, Chris Hornung, Jerry Habuda und Joseph Perino. Die Aktionäre stimmten auch dem Plan der Vereinbarung zu, der die Verteilung von Stammaktien der Weed Points Loyalty Inc. Dba TechOneSixty ("Weed Points") an die Aktionäre der Gesellschaft beinhaltet.
Das Unternehmen gibt auch bekannt, dass es in den letzten 60 Tagen einen Erlös von $ 1.858.760 aus der Ausübung von Optionsscheinen erhalten hat. Die Einkünfte beziehen sich auf allgemeine Betriebskapitalzwecke.
Das Unternehmen meldet außerdem, dass Sicherheitskomponenten in der Wachstumsanlage London, ON angekommen sind und die Installation der notwendigen Sicherheitsverbesserungen und -protokolle im Gange ist.
Zander2016 : Hab mich
So hat laut Angabe von Puf-Vent. MYM nur 35% Anteil an den neuen Gewächshäusern in Australien.
Zudem ist ja auch noch der Vertrag zum Verkauf von Marihuana an Canopy Groth der auch schön zu Buche schlagen wird.
Also für mich ein klares Langzeitinvestment!!!
Soll keine Kaufaufforderung für Euch sein!
anderswo : kam eben via mail
PUF Ventures Australia Files for Medical Research License in Collaboration with Western Sydney University
Vancouver, British Columbia / December 4th, 2017 ? PUF Ventures Inc. (?PUF? or the ?Company?) (CSE: PUF) (Frankfurt: PU3) (OTCPK: PUFXF), an advanced Access to Cannabis for Medical Purposes Regulations (?ACMPR?) license applicant, is pleased to announce that PUF Ventures Australia ("PUFA") has filed application with the Australian Office of Drug Control to obtain a medicinal cannabis license and a cannabis research license in collaboration with the National Institute of Complementary Medicine (NICM), an Australian Health Research Institute based at Western Sydney University in New South Wales (NSW), Australia.
PUF Ventures Australia aims to conduct medical research with NICM?s academic input at its proposed Northern Rivers Project, in a 10,000-square foot dedicated laboratory, training center and research facility. When complete the facility will include an extensive 1,200,000 square feet medicinal cannabis cultivation greenhouse and extraction plant, to be located near Casino, NSW. PUF Ventures Inc. and MYM Nutraceutical are partners in the Northern Rivers Project.
?NICM is a world-class research institute, and this collaboration will allow for access to our planned state-of-the-art labs and greenhouse facilities,? said Michael Horsfall, CEO, PUF Ventures Australia. ?NICM will provide their independent academic expertise to contribute to PUFA?s research agenda. This is a significant step forward to allow PUF Ventures Australia to focus on its mandate to develop innovative medicinal products.?
Professor Jerome Sarris, NICM Deputy Director sees tremendous mutual value in this evolving research relationship.
?As an institute specializing in medicinal plant research, to collaborate with an organization such as PUF Ventures Australia, with a grand and inspiring vision, holds significant medical potential,? said Professor Sarris. ?There is a growing global appetite for ?clean-green? high-quality medicinal plants, and in particular, medicinal cannabis, which presents immense health opportunities. NICM engages in selective research collaborations in medicinal cannabis, and the PUFA Northern Rivers Project is a significant development in the field which we are proud to be involved with.?
The Northern Rivers Project is working with experts in Australia, Europe, and Canada in support of the application with the Australian government. The application will further scientific and medical research in the field of medicinal cannabis. PUF Ventures Australia is presently in discussions with NICM on a range of potential projects including women?s health disorders, multiple sclerosis, immune disorders, and the optimization of cannabis constituent profiles.
Western Sydney University?s NICM is Australia?s leader in integrative and complementary medicine research and policy. Seed funded by the Commonwealth and NSW State Governments, NICM plays a key national role in ensuring Australians have access to reliable evidence on complementary medicines and treatments in wide use. As an ERA 5 ranking institute, NICM is globally recognized for its world-class research and innovations in integrative and complementary medicine. More information is available at www.nicm.edu.au.
About Northern Rivers Project
The Northern Rivers Project is a joint venture between PUF Ventures, PUF Ventures Australia, and MYM Nutraceutical, to build a 1.2 million square foot greenhouse operation on a 27-hectare parcel of land near the town of Casino in northern New South Wales, Australia. The operation when complete will include large-scale greenhouse, manufacturing, processing and office facilities for the cultivation, production and manufacture of medical cannabis and associated products in Australia. The first phase of the project will cover approximately 300,000 square feet, which will be the largest medical cannabis greenhouse in Australia.
About MYM Nutraceuticals Inc.
MYM Nutraceuticals Inc. is an innovative company focused on acquiring Health Canada licenses to produce and sell high-end organic medicinal cannabis supplements and topical products. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors. MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE: MYM) (OTC: MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY
Eberhard01 : @ Mr.Cashh
Manchmal hilft es auch, die Unternehmens News zu einem bestimmten Thema mal wieder durch zu lesen.